id:"swepub:oai:DiVA.org:uu-156005"
Search: id:"swepub:oai:DiVA.org:uu-156005" > Ticagrelor versus c...
- 1 of 1
- Previous record
- Next record
- To hitlist
- James, Stefan K.Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Institutionen för medicinska vetenskaper (author)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management : substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial
- Article/chapterEnglish2011
Publisher, publication year, extent ...
- 2011-06-17
- BMJ,2011
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:uu-156005
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-156005URI
- https://doi.org/10.1136/bmj.d3527DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Objective To evaluate efficacy and safety outcomes in patients in the PLATelet inhibition and patient Outcomes (PLATO) trial who at randomisation were planned for a non-invasive treatment strategy. Design Pre-specified analysis of pre-randomisation defined subgroup of prospective randomised clinical trial. Setting 862 centres in 43 countries. Participants 5216 (28%) of 18 624 patients admitted to hospital for acute coronary syndrome who were specified as planned for non-invasive management. Interventions Randomised treatment with ticagrelor (n=2601) versus clopidogrel (2615). Main outcome measurements Primary composite end point of cardiovascular death, myocardial infarction, and stroke; their individual components; and PLATO defined major bleeding during one year. Results 2183 (41.9%) patients had coronary angiography during their initial hospital admission, 1065 (20.4%) had percutaneous coronary intervention, and 208 (4.0%) had coronary artery bypass surgery. Cumulatively, 3143 (60.3%) patients had been managed non-invasively by the end of follow-up. The incidence of the primary end point was lower with ticagrelor than with clopidogrel (12.0% (n=295) v 14.3% (346); hazard ratio 0.85, 95% confidence interval 0.73 to 1.00; P=0.04). Overall mortality was also lower (6.1% (147) v 8.2% (195); 0.75, 0.61 to 0.93; P=0.01). The incidence of total major bleeding (11.9% (272) v 10.3% (238); 1.17, 0.98 to 1.39; P=0.08) and non-coronary artery bypass grafting related major bleeding (4.0% (90) v 3.1% (71); 1.30, 0.95 to 1.77; P=0.10) was numerically higher with ticagrelor than with clopidogrel. Conclusions In patients with acute coronary syndrome initially intended for non-invasive management, the benefits of ticagrelor over clopidogrel were consistent with those from the overall PLATO results, indicating the broad benefits of P2Y12 inhibition with ticagrelor regardless of intended management strategy.
Subject headings and genre
- MEDICINE
- MEDICIN
Added entries (persons, corporate bodies, meetings, titles ...)
- Roe, Matthew T. (author)
- Cannon, Christopher P. (author)
- Cornel, Jan H. (author)
- Horrow, Jay (author)
- Husted, Steen (author)
- Katus, Hugo (author)
- Morais, Joao (author)
- Steg, Ph Gabriel (author)
- Storey, Robert F. (author)
- Stevens, Susanna (author)
- Wallentin, LarsUppsala universitet,Uppsala kliniska forskningscentrum (UCR),Institutionen för medicinska vetenskaper(Swepub:uu)larswall (author)
- Harrington, Robert A. (author)
- Uppsala universitetUppsala kliniska forskningscentrum (UCR) (creator_code:org_t)
Related titles
- In:The BMJ: BMJ342, s. d3527-1756-1833
- In:BMJ: BMJ342, s. d3527-0959-81381468-5833
Internet link
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
